Sending Office: Rush, Bobby L.
Supported by: ZERO – The End of Prostate Cancer, American Urological Association (AUA), Large Urology Group Practice Association (LUGPA),
Cosponsors (27): Axne, Babin, Sanford D. Bishop Jr, Blunt Rochester, Susan W. Brooks, Butterfield, Carson, Chu, Clarke, Cohen, Dunn, Fitzpatrick, Anthony Gonzalez, Henry C. ‘Hank’ Johnson Jr., Jackson Lee, Kennedy, Peter T. King, Meeks,
Moore, Gregory F. Murphy, Pappas, Payne, Roe, David Scott, Sewell, Shimkus, Williams
Prostate cancer is the second leading cause of cancer death in men in the United States. For the millions of men who are at-risk of developing this cancer, an early diagnosis of the disease can be the difference between life and death. For those diagnosed
with early-stage prostate cancer, the survival rate is nearly 100 percent, but it is only 30 percent for late-stage prostate cancer.
African-American men are 70 percent more likely to be diagnosed with prostate cancer disease than white men. Additionally, men with a father or brother with prostate cancer are more than twice as likely to be diagnosed with prostate cancer than men without
a family history.
That is why we introduced H.R. 5200, the Prostate-Specific Antigen Screening for High-risk Insured Men (PSA Screening for HIM) Act. This bill would waive cost-sharing
— including deductibles, copayments, and coinsurances — for prostate cancer screenings for men who have a family history of prostate cancer or who are African-American. The removal of these barriers will help millions of at-risk men to diagnose this potentially
deadly cancer early.
We invite you to join us in cosponsoring the PSA Screening for HIM Act. To learn more or to cosponsor, please contact Lauren Citron in Rep. Rush’s office at Lauren.Citron@mail.house.gov or
Dylan Moore in Rep. Bucshon’s office at Dylan.Moore@mail.house.gov.
Bobby L. Rush
Member of Congress
Member of Congress
e-Dear Colleague version 2.0